These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21513712)

  • 41. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation.
    Gribar SC; Anand RJ; Sodhi CP; Hackam DJ
    J Leukoc Biol; 2008 Mar; 83(3):493-8. PubMed ID: 18160540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of Toll-like receptor signalling in the pathogenesis of arthritis.
    Brentano F; Kyburz D; Schorr O; Gay R; Gay S
    Cell Immunol; 2005 Feb; 233(2):90-6. PubMed ID: 15963480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
    Makkouk A; Abdelnoor AM
    Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toll-like receptors in ocular surface diseases: overview and new findings.
    Lambiase A; Micera A; Sacchetti M; Mantelli F; Bonini S
    Clin Sci (Lond); 2011 May; 120(10):441-50. PubMed ID: 21271987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction.
    O'Neill LA
    Immunity; 2008 Jul; 29(1):12-20. PubMed ID: 18631453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pound the alarm: danger signals in rheumatic diseases.
    O'Reilly S
    Clin Sci (Lond); 2015 Mar; 128(5):297-305. PubMed ID: 25394289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toll-Like Receptors Gene Polymorphisms in Autoimmune Disease.
    Zhang Y; Liu J; Wang C; Liu J; Lu W
    Front Immunol; 2021; 12():672346. PubMed ID: 33981318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toll-like receptors and NOD-like receptors in rheumatic diseases.
    McCormack WJ; Parker AE; O'Neill LA
    Arthritis Res Ther; 2009; 11(5):243. PubMed ID: 19835640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exercise as a therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic diseases.
    Perandini LA; de Sá-Pinto AL; Roschel H; Benatti FB; Lima FR; Bonfá E; Gualano B
    Autoimmun Rev; 2012 Dec; 12(2):218-24. PubMed ID: 22776785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type I interferon in rheumatic diseases.
    Muskardin TLW; Niewold TB
    Nat Rev Rheumatol; 2018 Mar; 14(4):214-228. PubMed ID: 29559718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Accelerated telomere shortening in rheumatic diseases: cause or consequence?
    Dehbi AZ; Radstake TR; Broen JC
    Expert Rev Clin Immunol; 2013 Dec; 9(12):1193-204. PubMed ID: 24215409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Damage-associated molecular patterns and chronic diseases].
    Yang HZ; Cai WF; Hu ZW
    Sheng Li Ke Xue Jin Zhan; 2009 Jul; 40(3):234-40. PubMed ID: 19803428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trained immunity and inflammation in rheumatic diseases.
    Badii M; Gaal O; Popp RA; Crișan TO; Joosten LAB
    Joint Bone Spine; 2022 Jul; 89(4):105364. PubMed ID: 35219890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autoimmune rheumatic disease and sleep: a review.
    Sangle SR; Tench CM; D'Cruz DP
    Curr Opin Pulm Med; 2015 Nov; 21(6):553-6. PubMed ID: 26402614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osteoporosis in Rheumatic Diseases.
    Adami G; Fassio A; Rossini M; Caimmi C; Giollo A; Orsolini G; Viapiana O; Gatti D
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of TLR signaling pathways by microRNAs: implications in inflammatory diseases.
    Arenas-Padilla M; Mata-Haro V
    Cent Eur J Immunol; 2018; 43(4):482-489. PubMed ID: 30799997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Role of Toll-like receptors in etiology of selected diseases of the skin].
    Kulczycka L; Sysa-Jędrzejowska A; Robak E
    Postepy Hig Med Dosw (Online); 2010 Aug; 64():364-71. PubMed ID: 20966494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research.
    Davies K; Dures E; Ng WF
    Nat Rev Rheumatol; 2021 Nov; 17(11):651-664. PubMed ID: 34599320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The danger model approach to the pathogenesis of the rheumatic diseases.
    Pacheco-Tena C; González-Chávez SA
    J Immunol Res; 2015; 2015():506089. PubMed ID: 25973436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peptide-Based Vaccination Therapy for Rheumatic Diseases.
    Wang B; Chen S; Zheng Q; Liu Y; Shi G
    J Immunol Res; 2020; 2020():8060375. PubMed ID: 32258176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.